IS4

IS4 is a selective competitive antagonist of CXCR4, exhibiting an IC50 of 0.65 nM in THP-1 cells and 38.75 nM in Jurkat cells. It remains stable in serum and is non-cytotoxic. IS4 competes with CXCL12 for binding to CXCR4, thereby inhibiting CXCL12-induced intracellular Ca2+ release and cancer cell migration. This compound is applicable in research on the prevention of metastasis in conditions such as breast cancer, prostate cancer, and leukemia.